Loading
Immune Cells in Cancer / Ferroptosis and Cancer Prognosis · Journal article
Molecular Medicine · August 8, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study in mouse models demonstrating that FXR loss or inhibition promotes colorectal liver metastasis through activation of a gutFXR–FGF15–PPARγ–VEGFα–MDSC signaling axis. The work identifies myeloid-derived suppressor cells as cellular mediators and proposes this axis as a therapeutic target, but provides no clinical efficacy data or human validation.
Preclinical mechanistic study in mouse models. Mouse preclinical models of colorectal liver metastasis; no human subjects.. Intervention: FXR knockout or Ursodeoxycholic Acid (UDCA) treatment in mouse CRLM models. Compared with: Implicitly wild-type or untreated controls, not explicitly described.
FXR knockout or UDCA treatment promoted CRLM in mouse models Single-cell sequencing, flow cytometry, and antibody depletion identified MDSCs as primary cellular mediators of FXR's effect on CRLM prognosis The gutFXR–FGF15–PPARγ–VEGFα–MDSC axis regulates MDSC accumulation and promotes liver metastasis of colon cancer
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This mechanistic work does not yet support clinical practice changes. It proposes the FXR-mediated axis as a potential therapeutic target for CRLM prevention and treatment, but requires validation in human studies before any therapeutic application.
Preclinical mechanistic study in mouse models identifying a signaling axis and proposing a therapeutic target, without human efficacy data or clinical validation.
As stated by the source record.
This mechanistic work does not yet support clinical practice changes. It proposes the FXR-mediated axis as a potential therapeutic target for CRLM prevention and treatment, but requires validation in human studies before any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer (CRC) and colorectal liver metastasis (CRLM) posed significant challenges in cancer management. To develop more effective therapies, we investigated the role of Farnesoid X Receptor (FXR, Nr1h4) in the tumor-liver microenvironment, an area with substantial therapeutic potential that had been underexplored. Employing preclinical mouse models of CRLM, we conducted a comprehensive evaluation of FXR expression and its functional significance in modulating the tumor-liver microenvironment. Techniques utilized included histological analysis, single-cell sequencing, immunohistochemistry (IHC), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Antibody depletion experiments, as well as the use of inhibitors and antagonists, were conducted to elucidate the mechanisms underlying FXR's role in colorectal cancer liver metastases. Our findings indicated that FXR knockout or treatment with Ursodeoxycholic Acid (UDCA) promoted CRLM. Single-cell sequencing, FCM, and antibody depletion experiments revealed that FXR affected CRLM prognosis by altering the liver microenvironment, with myeloid-derived suppressor cells (MDSCs) identified as the primary cellular mediators in this process. Mechanistically, the gutFXR-FGF15-PPARγ-VEGFα-MDSC axis played a crucial role in MDSC accumulation, thereby promoting liver metastasis of colon cancer. Our study uncovered a novel function of FXR in regulating the liver microenvironment and influencing CRLM progression. Targeting the gutFXR-FGF15-PPARγ-VEGFα-MDSC axis may offer a promising therapeutic strategy for the prevention and treatment of CRLM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.